Zeda, a provider of healthcare solutions, announced the acquisition of The Orthopaedic Implant Company (OIC), an orthopaedic implant company. Zeda is also known for its use of additive manufacturing.
OIC has set the standard in the US with its expertise in value-based implants and is recognized as a pioneer in high-quality, cost-effective orthopaedic devices. The acquisition will enable Zeda to produce OIC’s proven implant designs, significantly strengthening and accelerating the company’s mission to make high-quality trauma implants accessible worldwide.
Commenting on the acquisition, Shri Shetty, CEO of Zeda, expressed excitement about the collaboration: “The acquisition of OIC represents a pivotal moment for Zeda. Its leadership in value-based implants perfectly complements our additive manufacturing technologies that can deliver high quality orthopaedic devices and implants that are accessible to all patients, regardless of country and socioeconomic status. Together, our strengths and expertise will raise the standard of care globally and equitably for the world’s entire population.”
Itai Nemovicher, CEO and Co-Founder of The Orthopaedic Implant Company, also shared his perspective on the acquisition: “We are proud to join forces with Zeda, a company that shares in our values and dedication to advancing access to critical orthopaedic care because it can and should be done. Under Zeda, OIC will reach new heights in providing cost-effective, high-quality orthopaedic solutions in the US and abroad.”
Under the terms of the acquisition by Zeda, OIC will operate globally as a Zeda Health company. The deal solidifies Zeda’s position in the global orthopaedic industry as a company that develops and utilizes leading design and manufacturing technologies to advance device design while dramatically improving affordability and access to excellent care.
Subscribe to our Newsletter
3DPresso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.
